.png)
FAQ
Mounjaro (Tirzepatide) is a dual GLP-1 and GIP receptor agonist. It is used for both diabetes and weight management treatment.
Slows gastric emptying
It makes food move more slowly from the stomach into the intestines.
This helps reduce post-meal blood sugar spikes and increases feelings of fullness.
Acts on the brain to reduce appetite
Mounjaro interacts with both the GLP-1 & GIP receptors in appetite-regulation areas of the brain.
This leads to reduced hunger and lower food intake, contributing to weight loss
Mounjaro (Tirzepatide) is a once weekly injection.
It is injected just under the skin (subcutaneously) into the abdomen, thigh or upper arm.
Watch our helpful video on how to administer your injection
The initial dose is usually low, to minimise side effects, and is gradually increased based on the individual's response and tolerance. If you are beginning on Mounjaro (Tirzepatide), please be assured you will receive training and guidance on proper injection techniques and dosing schedules.
Results can vary, but most people start seeing weight loss within the first few weeks of taking the injections. Generally, you can expect to lose at least 5% of your body weight within 12 weeks. On Mounjaro, you might see up to a 22% weight loss over about 72 weeks, while on Wegovy, you can expect around a 15-17% loss. **New England Journal of Medicine (2025) - Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
As humans, we're all different, so the amount of time it takes to work can vary from person to person. However, most people start seeing results in terms of weight loss within the first few weeks of taking the injections.
As a general guide, most people are expected to lose at least 5% of their body weight within 12 weeks of starting treatment.
On Mounjaro, you can expect to see up to a 22% weight loss over about 72 weeks.
In a similar time frame on Wegovy, you should expect to see about a 15-17% loss**
**New England Journal of Medicine (2025) - Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Each Mounjaro pen contains 4 doses, with one injection per week. So, each pen will last you four weeks.
Mounjaro is generally well-tolerated, but it can cause side effects. Common ones include nausea, vomiting, diarrhoea, abdominal pain, indigestion, and constipation. These usually resolve as your body adjusts. Less common side effects may include pancreatitis, gallstones, inflammation of the gall bladder, and severe hypoglycemia, especially when used with certain diabetes medications. Always monitor for severe symptoms and seek medical attention if needed.
Mounjaro is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or in individuals with Multple Endocrine Neoplasia syndrome type 2.
The safety and efficacy of Mounjaro in pregnant and breastfeeding women have not been established. Animal studies have shown potential adverse effects on the fetus, so it should not be used during pregnancy or breast feeding.
Women with reproductive potential need to use contraception during treatment, however it should be noted that oral contraceptive may not be as effective whilst taking Mounjaro. For more information please speak with a member of the clinical team
Mounjaro should be stored in the refrigerator at 2ºC to 8ºC (36ºF to 46ºF) and protected from light.
It should not be frozen, and if accidentally frozen, it should be discarded.
After first use, the pen can be kept at room temperature (up to 30ºC/86ºF) for 30days.
If a dose is missed, it should be administered as soon as possible within 4 days after the missed dose.
If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.
In each case, you can then resume the regular once-weekly dosing schedule.
Reach out to our clinical team who can advise if you miss your dose:
01229 486700
If you have doubled up doses and/or believe you have overdosed with the medication, please get in touch with us immediately and we can schedule a call to review your clinical signs and symptoms.
Patients may experience gastrointestinal adverse reaction, including nausea.
There is no specific antidote for overdose of Mounjaro. A prolonged period of observation and treatment of these symptoms may be necessary, taking into account the half-life of Mounjaro (approximately 5 days).
Each individual will have a unique experience and treatment plan based on their progress and symptoms. If you are starting as a new customer not on any weight loss medication, you will begin month one with the starting dose of 2.5mg and then increase in month two to 5.0mg.
From here, the dosing schedule is individualised with dosage increased to 7.5mg > 10.0mg >12.5mg > 15.0mg.
Please be advised that our specialist nurses will review your reported progress and updates on a monthly basis and prescribe your next dose in line and according to the information provided.
Please ensure you return you monthly Well-Being survey. We are unable to increase your dose without receiving this or having a consultation with a member of the clinical team.
We’r here for the long term to ensure you reach your target and stay there! Speak with one of our Nurses who will discuss a personalised maintenance plan with you once you reach your target weight.
The good news is, you can also come back to us in the future if you're struggling down the line and want to recommence weight loss medications.